Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
March 06, 2024 16:09 ET | Source: Zymeworks Inc.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...
March 05, 2024 16:30 ET | Source: Zymeworks Inc.

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across...
February 27, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
February 14, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call

VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
February 08, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
January 31, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
January 04, 2024 06:15 ET | Source: Zymeworks Inc.

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Company well-positioned for further progress and broadening of R&D pipelineCash resources of approximately $455 million as of December 31, 2023 (unaudited)Expected cash runway, including proceeds...
January 04, 2024 06:00 ET | Source: Zymeworks Inc.

Zymeworks Announces Additional Leadership Appointments

Dr. Jeffrey Smith named Executive Vice President and Chief Medical OfficerDr. John Fann promoted to Senior VP, Process SciencesSeven new Vice Presidents appointed, underscoring commitment to...
December 26, 2023 08:00 ET | Source: Zymeworks Inc.

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today...